Delcath Systems (NASDAQ:DCTH) Issues Quarterly Earnings Results

Delcath Systems (NASDAQ:DCTH) issued its quarterly earnings results on Tuesday. The company reported ($0.48) EPS for the quarter, topping the consensus estimate of ($0.67) by $0.19, RTT News reports. The firm had revenue of $0.54 million for the quarter, compared to analysts’ expectations of $0.48 million. Delcath Systems had a negative net margin of 2,308.86% and a negative return on equity of 1,007.65%. During the same period in the previous year, the firm posted ($0.86) EPS.

Delcath Systems Stock Performance

NASDAQ DCTH opened at $5.09 on Thursday. The company has a current ratio of 3.30, a quick ratio of 3.11 and a debt-to-equity ratio of 0.08. The firm’s 50 day simple moving average is $4.34 and its 200 day simple moving average is $3.84. Delcath Systems has a 1 year low of $2.25 and a 1 year high of $7.99.

Analysts Set New Price Targets

A number of brokerages recently commented on DCTH. StockNews.com upgraded shares of Delcath Systems to a “sell” rating in a research note on Wednesday. HC Wainwright increased their target price on shares of Delcath Systems from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $18.50.

Insider Buying and Selling

In other news, Director Gil Aharon purchased 26,882 shares of Delcath Systems stock in a transaction that occurred on Tuesday, March 19th. The shares were acquired at an average price of $3.72 per share, for a total transaction of $100,001.04. Following the transaction, the director now owns 1,069,710 shares of the company’s stock, valued at approximately $3,979,321.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 21.10% of the stock is currently owned by company insiders.

Institutional Trading of Delcath Systems

A number of hedge funds have recently added to or reduced their stakes in the stock. Cibc World Market Inc. lifted its holdings in shares of Delcath Systems by 4.0% during the first quarter. Cibc World Market Inc. now owns 88,751 shares of the company’s stock worth $568,000 after purchasing an additional 3,432 shares during the period. Dimensional Fund Advisors LP acquired a new position in shares of Delcath Systems during the first quarter worth $75,000. Vanguard Group Inc. lifted its holdings in shares of Delcath Systems by 5.7% during the first quarter. Vanguard Group Inc. now owns 360,900 shares of the company’s stock worth $2,309,000 after purchasing an additional 19,605 shares during the period. Millennium Management LLC acquired a new position in shares of Delcath Systems during the second quarter worth $40,000. Finally, Tower Research Capital LLC TRC raised its stake in Delcath Systems by 107.8% during the first quarter. Tower Research Capital LLC TRC now owns 4,663 shares of the company’s stock worth $26,000 after buying an additional 2,419 shares during the last quarter. Institutional investors and hedge funds own 61.12% of the company’s stock.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.